<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26312698</article-id>
      <article-id pub-id-type="pmc">4540532</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20153651</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Pre-tibial myxedema: treatment with intralesional corticosteroid<xref ref-type="fn" rid="fn01">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ramos</surname>
            <given-names>Luana Oliveira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mattos</surname>
            <given-names>Paloma Corr&#xEA;a</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Figueredo</surname>
            <given-names>Giuseppe Lemos Pertoti</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maia</surname>
            <given-names>Alef Alioscha Andrade</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Romero</surname>
            <given-names>Sandra Adolfina Reys</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <aff id="aff01"><label>1</label>Universidade Federal do Amazonas (UFAM) - Manaus (AM),
Brazil.</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c01">MAILING ADDRESS: Luana Oliveira Ramos, Rua Apurin&#xE3; - Pra&#xE7;a 14, Centro,
69020-170 - Manaus - AM, Brazil. E-mail:
<email>oliv.luana@hotmail.com</email></corresp>
        <fn fn-type="conflict">
          <p>Conflict of Interest: None.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <volume>90</volume>
      <issue>3 Suppl 1</issue>
      <fpage>143</fpage>
      <lpage>146</lpage>
      <history>
        <date date-type="received">
          <day>24</day>
          <month>4</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>03</day>
          <month>6</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2015 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>The pretibial myxedema is a manifestation of Graves' disease characterized by
accumulation of glycosaminoglycans in the reticular dermis. The dermopathy is
self-limiting but in some cases may cause cosmetic and functional damage.
Conventional treatment is use of topical steroids under occlusive dressing, however
the intralesional application has shown good results. We present a case of pretibial
myxedema treated with single injection of intralesional corticosteroid.</p>
      </abstract>
      <kwd-group>
        <kwd>Adrenal cortex hormones</kwd>
        <kwd>Glucocorticoids</kwd>
        <kwd>Graves disease</kwd>
        <kwd>Myxedema</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Pretibial myxedema is a dermatological manifestation of Graves' disease, arising from a
local autoimmune response of the connective tissue, probably caused by antibodies
against receptors of thyroid-stimulating hormone (TSH).<sup><xref rid="r01" ref-type="bibr">1</xref></sup> Its prevalence varies from 0.5 to 4% in patients with
Graves' disease, and is more frequent (15%) in those who carry severe ophthalmopathy.
Even though the pathogenesis is uncertain, it is known that besides immunological
effects, mechanical factors, such as trauma and prolonged standing posture, contribute
to the formation of pretibial myxedema.<sup><xref rid="r02" ref-type="bibr">2</xref></sup></p>
      <p>The diagnosis is clinical, based on characteristics of pretibial lesions, presence of
Graves' ophthalmopathy and history of thyrotoxicosis. In doubtful cases, a biopsy may be
performed.<sup><xref rid="r03" ref-type="bibr">3</xref></sup></p>
      <p>Histologically, the tissue presents wide spaces between collagen bundles under
hematoxilin and eosin staining, showing accumulations of abundant mucopolysaccharides
acid between collagen bundles of dermis through Alcian blue, coloidal iron or toluidine
blue staining. It also presents normal or slightly elevated amount of fibroblasts; the
presence of TSH receptors in activated fibroblasts seems to be the largest piece in the
pathogenesis of dermatopathy. <sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r03" ref-type="bibr">3</xref></sup></p>
      <p>In general dermatopathy is self-limiting, however, advanced cases may present cosmetic
and functional damage. Application of occlusive corticoid directly over the lesion has
been reported as a successful therapeutic option in several studies, although the
clinical response diminishes when lesions are larger in size. <sup><xref rid="r01" ref-type="bibr">1</xref></sup> Recently, the use of intralesional corticoids has
demonstrated positive results with shorter treatment time.<sup><xref rid="r04" ref-type="bibr">4</xref>-<xref rid="r06" ref-type="bibr">6</xref></sup></p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>Male patient, 23 years old, was referred to the dermatology service complaining about an
asymptomatic lesion on the anterior face of lower third of right leg. At the
dermatological examination, a plaque with a shiny surface, measuring three centimeters,
with accentuation of follicular orifices similar to "orange peel" (<xref ref-type="fig" rid="f01">Figure 1</xref>) was observed. Upon palpation, it presented a firm and
non-depressible consistency. Clinical examination showed exophthalmos (<xref ref-type="fig" rid="f02">Figure 2</xref>). Diagnosed with Graves' disease for three
years, he underwent treatment with Tapazole 10mg and iodotherapy, and currently is using
levothyroxine for thyroid hormone replacement. Histopathological samples obtained by
incisional biopsy of lesions revealed accumulation of mucin in reticular dermis leading
to separation of collagen bundles. Epidermis and papillary dermis without abnormalities
(<xref ref-type="fig" rid="f03">Figures 3</xref> and <xref ref-type="fig" rid="f04">4</xref>). After diagnostic confirmation, the option was for intralesional
infiltration with corticosteroid. Triamcinolone 20mg/mL diluted with anesthetic
(lidocaine hydrochloride 2%) was used, reaching a concentration of 5mg/mLin a total
volume of 1.5 mL; the puncture was a single one, with a fan distribution pattern. The
lesion remitted 30 days after this single application, resulting in a brownish macule
(<xref ref-type="fig" rid="f05">Figure 5</xref>).</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Plaque with &#x201C;orange peel&#x201D; surface on anterior face of right leg</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0143-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Exophthalmos</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0143-g02"/>
      </fig>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Histopathological examination (H&amp;E, x40) showing epidermis and papillary
dermis without abnormalities. Accumulation of mucin in reticular dermis</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0143-g03"/>
      </fig>
      <fig id="f04" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Histopathological examination (H&amp;E, x100). Accumulation of mucin in reticular
dermis causing separation of collagen bundles</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0143-g04"/>
      </fig>
      <fig id="f05" orientation="portrait" position="float">
        <label>FIGURE 5</label>
        <caption>
          <p>Response after 1 application of intralesional corticosteroid</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0143-g05"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Graves' disease is an autoimmune disease of the thyroid gland which monitors the
production of directed autoantibodies mainly against the receptor of thyroid-stimulating
hormone (TSH). This is the most common cause of hyperthyroidism, which affects from 15
to 50 per 100.000 people a year, predominantly females. Characteristic clinical findings
include exophthalmos, pretibial myxedema and acropathy. These peripheral manifestations
of Graves' disease are prone to occur in a chronological order, exophthalmos first (in
30% of patients), followed by dermopathy (4% of patients) and then acropathy (less than
1% of patients). <sup><xref rid="r02" ref-type="bibr">2</xref></sup></p>
      <p>The clinical forms of pretibial myxedema may vary from one diffuse non-depressible
edema, found in the majority of cases, to nodules, plaques, polypoid lesions and
manifestations similar to elephantiasis. Although the most frequent site is the
pretibial region, its presentation may be in any part of the skin, including head,
trunk, limbs and under scars. Lesions may vary in color, and may look like "orange
peel", due to prominent hair follicles. Typically asymptomatic, they are rarely pruritic
or painful. In severe cases, associated with acropathy, osseous pain may result from an
underlying periosteal reaction. Hyperhidrosis, hypertrichosis and neuropathies have also
been reported. <sup><xref rid="r01" ref-type="bibr">1</xref>-<xref rid="r03" ref-type="bibr">3</xref></sup></p>
      <p>Treatment of pretibial myxedema aims to diminish the production of hyaluronic acid by
fibroblasts. Topical steroids with occlusive dressings and compression, intralesional
steroids, systemic corticosteroids, pentoxifylline, gamma globulin, plasmapheresis,
surgical excision and immunotherapy have been employed with varied success rates.
<sup><xref rid="r01" ref-type="bibr">1</xref></sup></p>
      <p>Many times the lesion remits spontaneously, with the drug treatment used purely for
cosmetic interests. Corticoids are the first indication for drug treatment of pretibial
myxedema lesions, administered as an occlusive dressing; however, application of
intralesional corticoid has already been approved as an efficient therapy, with good
results. <sup><xref rid="r04" ref-type="bibr">4</xref>-<xref rid="r06" ref-type="bibr">6</xref></sup></p>
      <p>In order to achieve remission of lesions with topical application it is necessary to
apply it as an occlusive dressing every night, during 4 to 6 weeks. <sup><xref rid="r01" ref-type="bibr">1</xref></sup> In comparison with corticoid
intralesional injection treatments, which present the remission of lesion with a monthly
injection, the topical treatment is slower and more laborious for the patient. The
adverse effects reported with the use of intralesional corticoids are related with the
onset of hyperpigmentation, atrophy and irregularities on the surface of skin.
<sup><xref rid="r01" ref-type="bibr">1</xref></sup></p>
      <p>The responses to the intralesional corticoid vary according to the patient. The conduct
was acceptable considering its resolubility and the benign character of lesion.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p>Financial Support: None.</p>
      </fn>
      <fn fn-type="other">
        <p><bold>How to cite this article:</bold> Ramos LO, Mattos PC, Figueredo GLP, Maia AAA,
Romero SAR. Pre-tibial myxedema: treatment with intralesional corticosteroid . An
Bras Dermatol. 2015;90 (3 Suppl 1):S143-6.</p>
      </fn>
      <fn fn-type="other" id="fn01">
        <label>*</label>
        <p>Work performed at Hospital Universit&#xE1;rio Get&#xFA;lio Vargas - Universidade Federal do
Amazonas (HUGV-UFAM) - Manaus (AM), Brazil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fatourechi</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Pretibial Myxedema - Pathophysiology and Treatment
Options</article-title>
          <source>Am J Clin Dermatol</source>
          <year>2005</year>
          <volume>6</volume>
          <fpage>295</fpage>
          <lpage>309</lpage>
          <pub-id pub-id-type="pmid">16252929</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anderson</surname>
              <given-names>CK</given-names>
            </name>
            <name>
              <surname>Miller 3rd</surname>
              <given-names>OF</given-names>
            </name>
          </person-group>
          <article-title>Triad of exophthalmos, pretibial mydema, and acropachy in a patient
with Graves&#xB4; disease</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2003</year>
          <volume>48</volume>
          <fpage>970</fpage>
          <lpage>972</lpage>
          <pub-id pub-id-type="pmid">12789197</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schwartz</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Fatourechi</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Ahmed</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Pond</surname>
              <given-names>GR</given-names>
            </name>
          </person-group>
          <article-title>Dermopathy of Graves' Disease(Pretibial Myxedema): Long-Term
Outcome</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2002</year>
          <volume>87</volume>
          <fpage>438</fpage>
          <lpage>446</lpage>
          <pub-id pub-id-type="pmid">11836263</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vannucchi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Campi</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Covelli</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Forzenigo</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Beck-Peccoz</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Salvi</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Treatment of Pretibial Myxedema with Dexamethazone Injected
Subcutaneously by Mesotherapy Needles</article-title>
          <source>Thyroid</source>
          <year>2013</year>
          <volume>23</volume>
          <fpage>626</fpage>
          <lpage>632</lpage>
          <pub-id pub-id-type="pmid">23397966</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Engin</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>G&#xFC;m&#xFC;sel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ozdemir</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cakir</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Successful combined pentoxifylline and intralesional triamcinolone
acetonide treatment of severe pretibial myxedema</article-title>
          <source>Dermatol Online J</source>
          <year>2007</year>
          <volume>13</volume>
          <fpage>16</fpage>
          <lpage>16</lpage>
          <pub-id pub-id-type="pmid">17498435</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deng</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Multipoint subcutaneous injection of long-acting glucocorticid as a
cure for pretibial myxedema</article-title>
          <source>Thyroid</source>
          <comment>201</comment>
          <volume>21</volume>
          <fpage>83</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="pmid">21162684</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
